|Year : 2019 | Volume
| Issue : 3 | Page : 443-449
Glucose transporter 1 in health and disease
Sindhuri Pragallapati1, Ravikanth Manyam2
1 Department of Oral Pathology, Vishnu Dental College, Bhimavaram, Andhra Pradesh, India
2 Head of the Department, Department of Oral Pathology, Vishnu Dental College, Bhimavaram, Andhra Pradesh, India
|Date of Submission||02-Feb-2018|
|Date of Acceptance||27-Jun-2019|
|Date of Web Publication||19-Dec-2019|
Sri Chaitanya Dental Clinic, Near RTC Bus Stand, Jangareddygudem - 534 447, West Godavari, Andhra Pradesh
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Glucose, a major source of energy for all cells, is transported into cells with the help of glucose transporters (GLUTs). These transporters are of two types, namely sodium-dependent GLUTs and facilitative GLUTs. These transporters are present in a tissue-specific pattern and have substrate specificity. Among these transporters, GLUT1 (facilitative GLUT) is present ubiquitously on all tissues of the body and helps in the basal uptake of glucose. GLUT1 is known to have many physiological functions in the body from the time of implantation of an embryo and is also seen associated with pathologies, including cancers. This review mainly focuses on GLUT1 in physiological and pathological conditions and the recent advances related to its role in cancer development and applications in cancer therapeutics.
Keywords: Glucose transporter 1, GLUT 1, pathology, physiology
|How to cite this article:|
Pragallapati S, Manyam R. Glucose transporter 1 in health and disease. J Oral Maxillofac Pathol 2019;23:443-9
| Introduction|| |
Carbohydrates are one of the four major classes of organic molecules in the living systems that help in energy production, long-term storage of energy, the formation of nucleic acids (ribose and deoxyribose) and in the detoxification process. They also function as signaling, recognition and adhesion molecules. Nowadays, it is known that aberrations in cell surface carbohydrates are involved in malignant cell transformation, invasion and metastasis., The majority of carbohydrates available in the dietary food are absorbed into the bloodstream in the form of glucose. Glucose acts as a major source of energy, plays a central role in metabolism, cellular homeostasis and act as an important substrate for protein and lipid synthesis. It can also be converted into other carbohydrates which carry out specific functions in the body.,, The transport of this essential hydrophilic glucose molecule across the hydrophobic plasma membrane is mediated by a group of membrane-associated carrier proteins called glucose transporters (GLUTs). There are two types of GLUTs which belong to the solute carrier gene series (SLC). They are (a) sodium-coupled carrier proteins (sodium-glucose co-transporter [SGLT]) and (b) facilitative GLUTs. SGLT (gene name SLC5A) family comprise of cotransporters that mediate transport of glucose and galactose by an active process. SGLT1 is a high-affinity, low-capacity transporter protein expressed mainly in the intestine, heart and kidney. SGLT2 is a low-affinity, high-capacity symporter which is ubiquitously present with the highest expression in the kidney. GLUT (gene name SLC2A) family comprise of facilitative transporters that transport hexose molecules down the concentration gradient in a tissue- and substrate-specific manner. There are 14 members in this group are numbered according to their order of discovery and are subdivided into three subfamilies according to sequence similarities, characteristic elements and functional characteristics. Brief details of these 14 GLUTs have been described in [Table 1].,, Among these transporters, GLUT1 is present on all cells to provide basal glucose uptake and is known to be elevated in various physiological and pathological conditions. This review mainly focuses on GLUT1 in physiological and pathological conditions and the recent advances related to its role in cancer development and applications in cancer therapeutics.
|Table 1: Description of details related to subclasses of glucose transporter 1 family arranged in order of their percentage identity [HMIT full form: H+/myoinositol cotransporter]|
Click here to view
| Glucose Transporter 1|| |
GLUT1 is an integral membrane hydrophobic protein that comprises of 492 amino acids with a molecular weight of 54 kDa. It helps in the transport of glucose, galactose, mannose, glucosamine and ascorbic acid. It is also known as erythrocyte/brain; HepG2 GLUT protein. GLUT1 is made up of 12 hydrophobic transmembrane α-helices with both N and C terminal on the cytoplasm side and a glycosylated extracellular loop between 1 and 2 transmembrane helices.
GLUT1 is present in human tissues with the highest levels of expression in plasma membranes of proliferating cells in the early development of an embryo. Postnatally during suckling phase, it is localized in high concentrations in the brain, skeletal muscle and myocardium, and in post-suckling phase and beyond into adult stages, there is a decline in the expression of GLUT1 except in the brain and there is an increase in the tissue-specific isoforms. In human erythrocytes, it comprises about 5%–10% of the total membrane protein.
It is seen widely in the cells forming various blood–tissue barriers. In cells forming blood–brain barriers; endothelial cells, astrocytes and choroid plexus express GLUT1. Retinal-pigmented epithelial cells, the choroidal, iridial, paras planus, retinal Mueller cells, lens fiber cells, iridial microvasculature endothelial cells and outer segments of the photoreceptor cells (lesser extent) of the blood–retinal barrier express GLUT1. The components of the perineurium and vascular endothelium of the blood–nerve barrier express GLUT1.
It is also seen in cardiac muscle, placenta and lactating mammary gland and has an important role in the development of the vertebrate brain. In insulin-sensitive tissues, such as adipose tissue and muscle, it is present in association with GLUT4.
Glucose transporter 1 functions in physiology
It helps in the implantation of the embryo by its increased expression in the endometrium and the basolateral surface of the polarized trophectodermal cells and the inner cell mass under the influence of the hormones estrogen and progesterone. Maternal diabetes with hyperglycemia is known to reduce the expression of GLUT1 which activates Bax leading to apoptosis, thereby causing embryo death.
It plays a vital role in maternal–placental glucose transport and also regulates the placenta–fetal glucose transport by enhancing its expression in the syncytiotrophoblastic cells and microvillus surface of the trophoblastic layer. This function of GLUT1 is supported by the coordinated expression of GLUT3 in the syncytiotrophoblastic layer.
In adults, it helps in providing glucose for energy production in red blood cells and brain. In muscle and adipose tissue, it helps in the transport of glucose during basal state. In active state and in times of hyperglycemia, GLUT4 expression is elevated due to the translocation of GLUT4 to the cell membrane by the action of insulin.,,
It helps in protection against insulin-resistant glucose uptake in the skeletal muscle caused by oxidative stress through regulation of the reactive oxygen species. It's expression on mitochondrial membrane helps in the transport of ascorbic acid into the mitochondria where it acts as an antioxidant and protects cells from oxidative damage.
Glucose transporter 1 in altered physiological conditions
During acute exercise, there is no change in the expression of GLUT1, but there is an increase in the expression of GLUT4. In exercise training, there is an increase in the expression of both GLUT1 and GLUT4 which help in increasing the insulin-stimulated glucose uptake in the trained muscles.
In hypoxia conditions, hypoxia-inducible factor which is normally present in the cells undergo transformation and regulate many genes that help in angiogenesis (such as vascular endothelial growth factor (EGF), inducible nitric oxide synthase), cell proliferation and survival (such as EGF, insulin-like growth factor-2, transforming growth factor-β) and for metabolic adaptations (such as glycolytic enzymes, GLUTs) that are essential for tumor growth, invasion and metastasis. The enhanced expression and function of GLUT-1 in response to hypoxia represents a fundamental adaptation that is critical to the maintenance of cellular homeostasis. Various mechanisms such as oxygen sensors theory, reduced adenosine triphosphate (ATP) or inhibition of phosphorylation theory and duration of hypoxia theory have been proposed to explain the activation of GLUT-1 in hypoxic conditions.,
Regulation of glucose transporter 1 expression
GLUT1 expression is mainly regulated by blood glucose concentration, cell signaling mechanisms and hormones. In hypoglycaemic states, there is an upregulation of GLUT1 in tissues such as brain where it helps in providing a major source of energy.
In normal cells, PIK3 (phosphoinositide 3-kinase)/Akt signaling pathway upregulates the transcription of GLUT1 mRNA through mammalian target of rapamycin complex 1 and 4E binding protein. Prolactin and hydrocortisone elevate the intracellular GLUT1 expression 15 times in mouse mammary epithelial cells. Thyroid hormones regulate the expression of GLUT1 and GLUT3 which has been studied in cerebral cortex of hypothyroid rat neonates where they have found the regulation of these proteins by T3 hormone.
| Glucose Transporter 1 Deficiency|| |
GLUT1 deficiency syndrome occurs due to impaired glucose transport into the brain either by de novo mutation in SLC2A1 gene or familial inheritance through autosomal-dominant inheritance pattern with complete penetrance. Few cases have been reported with autosomal recessive pattern of inheritance.
Clinical phenotypes of this disorder include: (a) classical phenotype, which was described in 1991 as an early-onset childhood epileptic encephalopathy. The characteristic features of this phenotype include epileptic encephalopathy with different seizure types, developmental delay, acquired microcephaly, complex movement disorders (variable combinations of ataxia, dystonia and spasticity) and paroxysmal events and (b) nonclassical phenotypes which are considered as variants of the classical phenotype. These are classified by Brockmann as (i) carbohydrate-responsive symptoms, characterized by a correlation between fasting and neurological deterioration including seizure frequency; (ii) predominant ataxia or dystonia, but without seizures and (iii) paroxysmal exertion-induced dyskinesia and seizures.
Nowadays the use of terms classical and nonclassical has limited clinical utility. Hence the disorder is studied in terms of its broad clinical spectrum which include: intellectual impairment, acquired microcephaly, epilepsy, movement disorders and hemolytic anemia. The condition is diagnosed by cerebrospinal fluid analysis, molecular analysis, erythrocyte 3-O methyl glucose uptake analysis, electroencephalography findings, positron emission tomography (PET) scans and brain imaging. Treatment option for the majority of these disorders is by administration of ketogenic diet.,
| Glucose Transporter 1 in Pathology|| |
Glucose metabolism in cancers
Warburg (1956) observed that cancer cells have high rates of aerobic glycolysis, which leads to the accumulation of lactate in the cancer cells. This increase in lactate production is due to upregulation of lactate dehydrogenase enzyme. The reduced pyruvate available for citric acid cycle decreases the production of ATP for energy requirement. Hence, more glucose has to enter cells for energy production by glycolysis through enhanced expression of GLUTs. This enhanced lactate dehydrogenase has been used as a prognostic marker in lymphomas, leukemia and colon cancer.
Other glucose metabolism enzymes known to be associated with cancers are glucose 6-phosphate dehydrogenase (cervical carcinomas, breast carcinomas) and 6-phosphogluconate dehydrogenase (cervical carcinomas). Modification of pyruvate kinase M2 isoform diverts the glucose flux for the production of components essential for cell proliferation and differentiation. This further mediates histone H3 phosphorylation which causes EGF-induced expression of cyclin D1 and c-myc, tumor cell proliferation, cell-cycle progression and brain tumorigenesis.
Relation between oncogenes and glucose transporter 1
Ras and Src oncogenes are known to enhance elements in the GLUT1 promoter region which leads to increased GLUT1 expression. This has been studied in rat fibroblasts where the transformation of cells with Ras, Src and Fujinami sarcoma virus has been done which resulted in increased glucose transport and GLUT1 expression.
c-Myc oncogene is known to be associated with upregulation of glycolysis by increasing the levels of glycolytic enzymes (lactate dehydrogenase and pyruvate kinase) and GLUT1.,,
Relation between tumor suppressor genes and glucose transporter 1
The tumor suppressor gene p53 which is known to be involved in the carcinogenesis of many tumors has implication in the alteration of expression of GLUT1.
p53, which is known for its regulation of normal growth and development, also regulates glycolysis and oxidative phosphorylation by inhibiting the expression of GLUT1 and GLUT4. Alterations or mutations in p53 leads to upregulation of glucose transporters, thereby enhancing the glucose influx required for energy production, proliferation and growth of cancer cells.,,
Relation between glucose transporter 1and apoptosis
GLUT1 is known to have an indirect relation with that of apoptosis various mechanisms have been described. This has been proved by conducting various studies on cancer cell lines of breast, colon, lung and gastric using GLUT1 antibodies increased apoptosis and reduction in tumor size due to the arrest of cell cycle in G1 phase.,, This has been used in clinical trials for inhibition of cell proliferation to know the efficacy of GLUT1 inhibitors in targeted therapy, thereby bringing new insights into cancer therapeutics.
Glucose transporter 1 in oral vascular lesions
GLUT1, which is normally expressed in the vasculature of blood–tissue barriers and placenta, is known to be used as a marker for differential diagnosis of various vascular lesions. It helps in differentiating hemangiomas which show diffuse positivity to GLUT1 from vascular malformations and pyogenic granulomas which show a negative reaction with GLUT1. These are frequently confused lesions due to their overlapping histological features and have to be differentiated because of their differing treatment strategies.,
Studies related to glucose transporter 1 in cancers
Altered metabolism is one of the adaptive mechanisms adopted by tumor cells to sustain in adverse conditions. This adaptive mechanism helps the tumors cells in continuing growth, proliferation and survival. GLUT1 which is considered as a gateway for the entry of glucose required for metabolism in cancer cells various studies have been conducted on tumors of the body to know the correlation between GLUT1 and biology of various cancers.
Various studies conducted on hepatic carcinomas, gastric carcinomas, cervical cancers,, renal cancers, colorectal cancers, pancreatic cancers, ovarian cancers, abdominal and mesothelial carcinomas, head and neck squamous cell carcinomas, lung adenocarcinomas, metastatic and nonmetastatic lip squamous cell carcinomas, breast carcinomas, endometrial carcinomas, verrucous carcinoma  and soft-tissue sarcoma  showed overexpression of GLUT1 which states that aerobic glycolysis is adapted as a fundamental mechanism in almost all types of tumors in the body, and it can be used as an immunodiagnostic marker in these tumors.,
The study conducted on benign melanocytic lesions and malignant melanomas showed contrasting findings reduced expression of GLUT1 has been observed in melanomas when compared to their benign counter lesion. This shows that other mechanisms play a role in the progression of melanoma and further studies have to be conducted to know its mechanism.
Studies related to prognostic applications of glucose transporter 1 in cancers
Increased expression of GLUT1 has been seen in many tumors, but few studies have correlated the expression of GLUT1 with the prognosis of the patients [Table 2].,,,, These studies have shown that increased expression of GLUT1 has been correlated with the poor survival of the patient.,,,,
|Table 2: Studies related to GLUT1 application in assessing prognosis of carcinomas|
Click here to view
Studies related to relation between 18 F-fluoro-2-deoxyglucose uptake and glucose transporter 1 in cancers
PET is a noninvasive nuclear medicine imaging technique that produces a three-dimensional image of functional processes in the body. The use of 2-deoxy-2-18fluoro-β-D glucose, which is an analog of glucose, helps in early detection of tumors and assesses the response to cancer therapy. The use of this scan as an adjuvant in oncology helps in understanding possible mechanisms of cancer biology and to determine the aggressiveness. The use of 18F-fluoro-2-deoxyglucose (FDG)-PET scan in combination with GLUT1 helps in understanding cancer metabolism.,
Various studies have been conducted on nonsmall cell lung carcinoma, cardiac myxoma, neuroendocrine tumors, colorectal adenocarcinomas, pancreatic tumors, lymphoma  and salivary gland pleomorphic adenomas  to know the relation between the cellular uptake of 18 F-FDG and expression of GLUT1. In all these tumors, they have found a positive correlation between 18 F-FDG uptake and GLUT1 expression.
Studies conducted on inflammatory lung lesions and reactive lymph nodes in oral cancer showed no correlation between uptake of 18 F-FDG and GLUT1 staining. Hence, it can be hypothesized false-positive results can be seen in associated with inflammatory lesions and nonmalignant tissues.,
Studies related to glucose transporter 1 in odontogenic cysts and tumors
Odontogenic cysts and tumors are the common lesions seen in the head-and-neck region. The expression of GLUT1 in these lesions has not been reported except a case report related to ameloblastoma.
Otsuru et al. conducted a study to investigate the usefulness of FDG-PET in diagnosing recurrent ameloblastoma. Furthermore, as GLUT-1 expression has been found to be involved with FDG uptake in numerous malignancies, they ascertained whether this also applies to ameloblastoma. They hypothesized that FDG-PET is useful in diagnosing recurrence and metastasis of various malignant tumors. If FDG-PET is useful for identifying ameloblastoma as a locally invasive tumor with a high rate of recurrence, early diagnosis of recurrent ameloblastoma may be possible. They have studied four cases of ameloblastoma which have shown diffuse expression of GLUT1 that has been correlated with the FDG uptake in those tumors.
| Use in Cancer Therapeutics|| |
Abnormal glucose metabolism, which is considered as one of the factors responsible for carcinogenesis, has been linked to drug resistance in cancer therapy. Research on targeting dysregulated metabolism is going on to overcome the therapeutic resistance and for improving the efficacy of cancer therapy. Targeting of glucose metabolism can be directed either toward glycolytic enzymes or GLUTs. GLUT targeting acts as a first rate-limiting step of glucose metabolism, as it prevents the entry of glucose into the cell. Various GLUT1 inhibitors available, their mechanism and site of action and its current status in research has been tabulated [Table 3].,, Other GLUT1 inhibitors include cryptocoryne, thiazolidinediones, methylxanthines and resveratrol which direct their action against GLUT1. The advantage with these inhibitors is that the normal cells are spared hence causing little harm to the patients.,,
| Future Perspectives|| |
Further investigations related to the detailed role of GLUT1 in the carcinogenesis process and research related to selective targeting and enhanced inhibitory efficacy of inhibitors have to be considered for formulating an effective anticancer therapeutics.
| Conclusion|| |
Glucose is the main source of energy for all the cells, including the transformed cells. Transport of glucose is carried out by transporter proteins, among this GLUT1 is ubiquitously present and overexpressed in transformed cells. GLUT1 plays a vital role both in physiology and pathology. Knowledge related to GLUT1 helps us in understanding its role in carcinomas and help us in formulating a better treatment plan for the patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ghazarian H, Idoni B, Oppenheimer SB. A glycobiology review: Carbohydrates, lectins and implications in cancer therapeutics. Acta Histochem 2011;113:236-47.
Murray RK, Grany DK, Mayer PA, Rodwell VW. Harper's Biochemistry: Carbohydrates. 25th
ed. USA: Lange Medical Books; 2000.
Scheepers A, Joost HG, Schürmann A. The glucose transporter families SGLT and GLUT: Molecular basis of normal and aberrant function. JPEN J Parenter Enteral Nutr 2004;28:364-71.
Zhao FQ, Keating AF. Functional properties and genomics of glucose transporters. Curr Genomics 2007;8:113-28.
Manolescu AR, Witkowska K, Kinnaird A, Cessford T, Cheeseman C. Facilitated hexose transporters: New perspectives on form and function. Physiology (Bethesda) 2007;22:234-40.
Carruthers A, DeZutter J, Ganguly A, Devaskar SU. Will the original glucose transporter isoform please stand up! Am J Physiol Endocrinol Metab 2009;297:E836-48.
Andrisse S, Koehler RM, Chen JE, Patel GD, Vallurupalli VR, Ratliff BA, et al.
Role of GLUT1 in regulation of reactive oxygen species. Redox Biol 2014;2:764-71.
Sagun KC, Cárcamo JM, Golde DW. Vitamin C enters mitochondria via facilitative glucose transporter 1 (Glut1) and confers mitochondrial protection against oxidative injury. FASEB J 2005;19:1657-67.
Barnard RJ, Youngren JF. Regulation of glucose transport in skeletal muscle. FASEB J 1992;6:3238-44.
Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004;9 Suppl 5:10-7.
Behrooz A, Ismail-Beigi F. Stimulation of glucose transport by hypoxia: Signals and mechanisms. News Physiol Sci 1999;14:105-10.
Ward PS, Thompson CB. Signaling in control of cell growth and metabolism. Cold Spring Harb Perspect Biol 2012;4:a006783.
De Giorgis V, Veggiotti P. GLUT1 deficiency syndrome 2013: Current state of the art. Seizure 2013;22:803-11.
Rotstein M, Engelstad K, Yang H, Wang D, Levy B, Chung WK, et al.
Glut1 deficiency: Inheritance pattern determined by haploinsufficiency. Ann Neurol 2010;68:955-8.
Macheda ML, Rogers S, Best JD. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005;202:654-62.
Wu W, Zhao S. Metabolic changes in cancer: Beyond the Warburg effect. Acta Biochim Biophys Sin (Shanghai) 2013;45:18-26.
Coller HA. Is cancer a metabolic disease? Am J Pathol 2014;184:4-17.
Osthus RC, Shim H, Kim S, Li Q, Reddy R, Mukherjee M, et al.
Deregulation of glucose transporter 1 and glycolytic gene expression by c-myc. J Biol Chem 2000;275:21797-800.
Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004;64:2627-33.
Xi Li, Luo HS, Paul SC, Tang T, Yuan GJ. Down regulation of the expression of GLUT1 plays a role in apoptosis induced by sodium butyrate in HT-29 cell line. Int J Mol Sci 2006;7:59-70.
Noguchi Y, Saito A, Miyagi Y, Yamanaka S, Marat D, Doi C, et al.
Suppression of facilitative glucose transporter 1 mRNA can suppress tumor growth. Cancer Lett 2000;154:175-82.
Rastogi S, Banerjee S, Chellappan S, Simon GR. Glut-1 antibodies induce growth arrest and apoptosis in human cancer cell lines. Cancer Lett 2007;257:244-51.
de Oliveira DH, da Silveira EJ, de Medeiros AM, Alves PM, Queiroz LM. Study of the etiopathogenesis and differential diagnosis of oral vascular lesions by immunoexpression of GLUT-1 and HIF-1α. J Oral Pathol Med 2014;43:76-80.
Johann AC, Salla JT, Gomez RS, de Aguiar MC, Gontijo B, Mesquita RA. GLUT-1 in oral benign vascular lesions. Oral Dis 2007;13:51-5.
Grobholz R, Hacker HJ, Thorens B, Bannasch P. Reduction in the expression of glucose transporter protein GLUT 2 in preneoplastic and neoplastic hepatic lesions and reexpression of GLUT 1 in late stages of hepatocarcinogenesis. Cancer Res 1993;53:4204-11.
Kim WS, Kim YY, Jang SJ, Kimm K, Jung MH. Glucose transporter 1 (GLUT1) expression is associated with intestinal type of gastric carcinoma. J Korean Med Sci 2000;15:420-4.
Airley R, Loncaster J, Davidson S, Bromley M, Roberts S, Patterson A, et al.
Glucose transporter glut-1 expression correlates with tumor hypoxia and predicts metastasis-free survival in advanced carcinoma of the cervix. Clin Cancer Res 2001;7:928-34.
Rudlowski C, Becker AJ, Schroder W, Rath W, Büttner R, Moser M. GLUT1 messenger RNA and protein induction relates to the malignant transformation of cervical cancer. Am J Clin Pathol 2003;120:691-8.
Ozcan A, Shen SS, Zhai QJ, Truong LD. Expression of GLUT1 in primary renal tumors: Morphologic and biologic implications. Am J Clin Pathol 2007;128:245-54.
Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, et al.
GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer 2009;9:241.
Basturk O, Singh R, Kaygusuz E, Balci S, Dursun N, Culhaci N, et al.
GLUT-1 expression in pancreatic neoplasia: Implications in pathogenesis, diagnosis, and prognosis. Pancreas 2011;40:187-92.
Semaan A, Munkarah AR, Arabi H, Bandyopadhyay S, Seward S, Kumar S, et al
. Expression of GLUT1 in epithelial ovarian carcinoma: Correlation with tumor cell proliferation, angiogenesis, survival and ability to predict optimal cytoreduction. Gynaecol Oncol 2011;121:181-6.
Lagana SM, Taub RN, Borczuk AC. Utility of glucose transporter 1 in the distinction of benign and malignant thoracic and abdominal mesothelial lesions. Arch Pathol Lab Med 2012;136:804-9.
Li S, Yang X, Wang P, Ran X. The effects of GLUT1 on the survival of head and neck squamous cell carcinoma. Cell Physiol Biochem 2013;32:624-34.
Maki Y, Soh J, Ichimura K, Shien K, Furukawa M, Muraoka T, et al.
Impact of GLUT1 and ki-67 expression on early-stage lung adenocarcinoma diagnosed according to a new international multidisciplinary classification. Oncol Rep 2013;29:133-40.
Demeda CF, Carvalho CH, Aquino AR, Nonaka CF, Souza LB, Pinto LP, et al.
Expression of glucose transporters 1 and 3 in metastatic and non-metastatic lower lip squamous cell carcinoma. Braz Dent J 2014;25:372-8.
Jiwa LS, van Diest PJ, Hoefnagel LD, Wesseling J, Wesseling P. Dutch Distant Breast Cancer Metastases Consortium. Upregulation of claudin-4, CAIX and GLUT-1 in distant breast cancer metastases. BMC Cancer 2014;14:864.
Ma X, Hui Y, Lin L, Wu Y, Zhang X, Liu P. Clinical significance of COX-2, GLUT-1 and VEGF expressions in endometrial cancer tissues. Pak J Med Sci 2015;31:280-4.
Angadi VC, Angadi PV. GLUT-1 immunoexpression in oral epithelial dysplasia, oral squamous cell carcinoma, and verrucous carcinoma. J Oral Sci 2015;57:115-22.
Kim JI, Choi KU, Lee IS, Choi YJ, Kim WT, Shin DH, et al.
Expression of hypoxic markers and their prognostic significance in soft tissue sarcoma. Oncol Lett 2015;9:1699-706.
Carvalho KC, Cunha IW, Rocha RM, Ayala FR, Cajaíba MM, Begnami MD, et al.
GLUT1 expression in malignant tumors and its use as an immunodiagnostic marker. Clinics (Sao Paulo) 2011;66:965-72.
Younes M, Lechago LV, Somoano JR, Mosharaf M, Lechago J. Wide expression of the human erythrocyte glucose transporter glut1 in human cancers. Cancer Res 1996;56:1164-7.
Parente P, Coli A, Massi G, Mangoni A, Fabrizi MM, Bigotti G, et al.
Immunohistochemical expression of the glucose transporters glut-1 and glut-3 in human malignant melanomas and benign melanocytic lesions. J Exp Clin Cancer Res 2008;27:34.
Kunkel M, Reichert TE, Benz P, Lehr HA, Jeong JH, Wieand S, et al.
Overexpression of glut-1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma. Cancer 2003;97:1015-24.
Kunkel M, Moergel M, Stockinger M, Jeong JH, Fritz G, Lehr HA, et al.
Overexpression of GLUT-1 is associated with resistance to radiotherapy and adverse prognosis in squamous cell carcinoma of the oral cavity. Oral Oncol 2007;43:796-803.
Endo M, Tateishi U, Seki K, Yamaguchi U, Nakatani F, Kawai A, et al.
Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. Jpn J Clin Oncol 2007;37:955-60.
Ohba S, Fujii H, Ito S, Fujimaki M, Matsumoto F, Furukawa M, et al.
Overexpression of GLUT-1 in the invasion front is associated with depth of oral squamous cell carcinoma and prognosis. J Oral Pathol Med 2010;39:74-8.
Harshani JM, Yeluri S, Guttikonda VR. Glut-1 as a prognostic biomarker in oral squamous cell carcinoma. J Oral Maxillofac Pathol 2014;18:372-8.
] [Full text]
Alauddin MM. Positron emission tomography (PET) imaging with (18) F-based radiotracers. Am J Nucl Med Mol Imaging 2012;2:55-76.
Avril N. GLUT1 expression in tissue and (18)F-FDG uptake. J Nucl Med 2004;45:930-2.
Okazaki Y, Yamada S, Kitada S, Matsunaga I, Nogami E, Watanabe T, et al.
Significance of 18 F-FDG PET and immunohistochemical GLUT-1 expression for cardiac myxoma. Diagn Pathol 2014;9:117.
Binderup T, Knigge UP, Federspiel B, Sommer P, Hasselby JP, Loft A, et al.
Gene expression of glucose transporter 1 (GLUT1), hexokinase 1 and hexokinase 2 in gastroenteropancreatic neuroendocrine tumors: Correlation with F-18-fluorodeoxyglucose positron emission tomography and cellular proliferation. Diagnostics (Basel) 2013;3:372-84.
Higashi T, Tamaki N, Torizuka T, Nakamoto Y, Sakahara H, Kimura T, et al.
FDG uptake, GLUT-1 glucose transporter and cellularity in human pancreatic tumors. J Nucl Med 1998;39:1727-35.
Koga H, Matsuo Y, Sasaki M, Nakagawa M, Kaneko K, Hayashi K. Differential FDG accumulation associated with GLUT-1 expression in a patient with lymphoma. Ann Nucl Med 2003;17:327-31.
Horiuchi C, Tsukuda M, Taguchi T, Ishiguro Y, Okudera K, Inoue T. Correlation between FDG-PET findings and GLUT1 expression in salivary gland pleomorphic adenomas. Ann Nucl Med 2008;22:693-8.
Mamede M, Higashi T, Kitaichi M, Ishizu K, Ishimori T, Nakamoto Y, et al.
[18F]FDG uptake and PCNA, glut-1, and hexokinase-II expressions in cancers and inflammatory lesions of the lung. Neoplasia 2005;7:369-79.
Nakagawa T, Yamada M, Suzuki Y. 18F-FDG uptake in reactive neck lymph nodes of oral cancer: Relationship to lymphoid follicles. J Nucl Med 2008;49:1053-9.
Otsuru M, Aoki T, Tsukinoki K, Ota Y, Karakida K, Yamazaki H, et al.
Usefulness of 18F-fluorodeoxyglucose positron emission tomography for detecting ameloblastoma, with special reference to glucose transporter-1 expression. J Oral Maxillofac Surg 2008;66:1761-5.
Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis 2013;4:e532.
Granchi C, Fancelli D, Minutolo F. An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg Med Chem Lett 2014;24:4915-25.
Qian Y, Wang X, Chen X. Inhibitors of glucose transport and glycolysis as novel anticancer therapeutics. World J Transl Med 2014;3:37-57.
[Table 1], [Table 2], [Table 3]